Discover one of our 28 local entrepreneurial communities »
Be the first to know as we launch in new countries and markets around the globe.
Interested in bringing MIT Technology Review to your local market?
Unsupported browser: Your browser does not meet modern web standards. See how it scores »
IBM’s Blue Gene supercomputer uncovers a novel drug interaction site.
A biotech company called Cerulean says its nanoparticle-delivered cancer drugs are better at attacking tumors.
They could be the cause of cancer relapse—but may also offer new approaches to treatment.
One startup, H3 Biomedicines, uses genome data to design drugs aimed at small groups of patients.
The new approach, which features a heat-sensitive fluorescent dye, could eventually replace standard chemotherapy.
By analyzing tumors, Foundation Medicine helps oncologists, pharma companies, and researchers combat the disease.
Tumors closer to committing “cellular suicide” are more sensitive to conventional anticancer drugs.
Researchers hope to combine the sensor with a device to deliver targeted chemotherapy.